FDA Review of Varenicline and Risk of Cardiovascular Adverse Events

Published Online: Wednesday, December 19, 2012
Follow Pharmacy_Times:
This podcast, from the Centers for Disease Control and Prevention, discusses a drug safety communication released by the FDA on December 12, 2012, regarding the risk of cardiovascular adverse events associated with the smoking-cessation drug varenicline (Chantix).
 
To download the podcast, click here.
Related Articles
Live medication therapy management (MTM) reduces low-density-lipoprotein cholesterol significantly more than standard, chart-review MTM.
The results of an FDA safety review of omalizumab (Xolair) suggest the asthma drug slightly elevates the risk of serious cardiovascular and cerebrovascular adverse events.
New late-stage trial data show ivabradine reduces cardiovascular death or hospitalization for worsening chronic heart failure in patients with low systolic blood pressure.
Latest Issues
$auto_registration$